Communiqués Novo Nordisk A/S

Actions

NOVO B

DK0062498333

Produits pharmaceutiques

PEA

Marché Fermé - Nasdaq Copenhagen Autres places de cotation 17:20:00 10/12/2025			Varia. 5j.	Varia. 1 janv.
309,10 ^DKK	+3,31 %		+1,74 %	-50,48 %

10/12	Les actions européennes cotées aux États-Unis sous forme d'ADR progressent lors des échanges de mercredi	MT
10/12	Wall Street : This is decision day

Communiqués

Novo Nordisk has completed its acquisition of Akero Therapeutics	09/12	GL
GLP-1 Agonists Market: Driving Innovation and Growth in Metabolic and Cardiovascular Care	08/12	AQ
Novo Nordisk A/S : Minutes and voting results from Extraordinary General Meeting 2025 ( novo nordisk egm 2025 minutes )	28/11	PU
Novo Nordisk A/S : Presentation from Extraordinary General Meeting 2025 ( egm presentation 2025 )	28/11	PU
Alzheimer's Phase III miss signals GLP-1RA combination therapy potential	25/11	AQ
Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes	25/11	GL
Novo Nordisk A/S, Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression	25/11	AQ
Federal Jury Clears Novo Nordisk in False Claims Act Case that Included Testimony by Analysis Group Affiliate Anupam Jena	25/11	AQ
Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression	24/11	GL
US stocks open higher at the start of a holiday-shortened week	24/11	AQ
Novo Nordisk Secures Trial Victory In Off Label Promotion, Kickback Case	19/11	AQ
Chromologics raises €7 million to bring its natural colour ingredients closer to market	18/11	AQ
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons	17/11	GL
Novo cuts Wegovy prices, but doctors still see cost challenges for patients	17/11	AQ
Resolutions from the Extraordinary General Meeting of Novo Nordisk A/S	14/11	GL
Novo Nordisk A/S: Candidate for the Board of Directors will not seek election	13/11	GL
Prothena Highlights Phase 2 Data for Coramitug Published in Circulation, Official Journal of AHA	12/11	AQ
Pfizer pays billions for Metsera and strengthens position in the obesity market	11/11	AQ
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons	11/11	GL
Pfizer's Metsera hunger sees it beat Novo Nordisk's obesity biopharma offer	10/11	AQ
Novo Nordisk will not increase its proposal to acquire Metsera, Inc.	10/11	AQ
Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk	08/11	AQ
Novo Nordisk A/S : will not increase its proposal to acquire Metsera, Inc.	08/11	PU
Novo Nordisk will not increase its proposal to acquire Metsera, Inc.	08/11	GL
AstraZeneca seals obesity deal as Pfizer-Novo Nordisk battle for Metsera	07/11	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Les USA font plonger les prix de 15 médicaments, dont le Wegovy de Novo Nordisk

Le 26 novembre 2025 à 06:41

Pas de long fleuve tranquille pour Novo Nordisk

Le 25 novembre 2025 à 13:14

La chute de la valorisation de Novo Nordisk est jugée excessive malgré la pression sur les prix et le revers subi dans le domaine de la maladie d'Alzheimer

Le 25 novembre 2025 à 10:42

Le comprimé Ozempic de Novo échoue dans la lutte contre Alzheimer

Le 24 novembre 2025 à 21:47